Literature DB >> 26544669

Loss of Mismatched HLA on the Leukemic Blasts of Patients With Relapsed Lymphoid Malignancies Following Bone Marrow Transplantation From Related Donors With HLA Class II Mismatches in the Graft Versus Host Direction.

Koichi Hirabayashi1, Takashi Kurata1, Kazuki Horiuchi2, Shoji Saito1, Tomonari Shigemura1, Miyuki Tanaka1, Ryu Yanagisawa1, Kazuyuki Matsuda2, Kazuo Sakashita1, Kenichi Koike1, Yozo Nakazawa1.   

Abstract

Mechanisms of relapse of acute lymphoblastic leukemia (ALL) after human leukocyte antigen (HLA) class II mismatched hematopoietic stem cell transplantation (HSCT) remain unclear. We report two children with relapsed ALL after HSCT from related donors with HLA-DRB1 and -DQB1 mismatches in the graft versus host direction. One lost HLA-DRB1, DQB1, and DPB1 alleles, and the other lost one HLA haplotype of the leukemic blasts at relapse. HLA class II loss may be a triggering event for ALL relapse after partially HLA-mismatched-related HSCT. In addition, HLA typing of relapsed leukemic blasts could be vital in the selection of retransplant donors.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  HLA class II; HLA loss; acute lymphoblastic leukemia; relapse; stem cell transplantation

Mesh:

Substances:

Year:  2015        PMID: 26544669     DOI: 10.1002/pbc.25819

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.

Authors:  Bronwen E Shaw
Journal:  Blood Adv       Date:  2017-02-14

Review 2.  Epidemiology and biology of relapse after stem cell transplantation.

Authors:  Mary Horowitz; Hans Schreiber; Alex Elder; Olaf Heidenreich; Josef Vormoor; Christina Toffalori; Luca Vago; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2018-04-18       Impact factor: 5.483

3.  Clinical Characteristics and Outcome Analysis for HLA Loss Patients Following Partially Mismatched Related Donor Transplantation Using HLA Chimerism for Loss of Heterozygosity Analysis by Next-Generation Sequencing.

Authors:  Andi Wang; Wenjun Li; Fei Zhao; Zhongzheng Zheng; Ting Yang; Sanbin Wang; Jinsong Yan; Jianpin Lan; Shengjin Fan; Mingfeng Zhao; Jianpin Shen; Xin Li; Tonghua Yang; Quanyi Lu; Ying Lu; Hai Bai; Haiyan Zhang; Dali Cai; Ling Wang; Zhiyang Yuan; Erlie Jiang; Fang Zhou; Xianmin Song
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

Review 4.  Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Authors:  Joseph C Rimando; Matthew J Christopher; Michael P Rettig; John F DiPersio
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

5.  Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide.

Authors:  Paula Muñiz; Mi Kwon; Diego Carbonell; María Chicano; Rebeca Bailén; Gillen Oarbeascoa; Julia Suárez-González; Cristina Andrés-Zayas; Javier Menárguez; Nieves Dorado; Ignacio Gómez-Centurión; Javier Anguita; José Luis Díez-Martín; Carolina Martínez-Laperche; Ismael Buño
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.